Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior to market open on Tuesday, May 8, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. Eastern Time to discuss the results.

Intercept management will also be presenting at the following upcoming investor conferences:

  • Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET on Wednesday, May 9, 2018
  • Bank of America Merrill Lynch 2018 Healthcare Conference at 5:00 p.m. PT on Tuesday, May 15, 2018
  • UBS Global Healthcare Conference at 3:00 p.m. ET on Monday, May 21, 2018
  • Jefferies 2018 Global Healthcare Conference at 9:00 a.m. ET on Friday, June 8, 2018

Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

CONTACT

For more information about Intercept Pharmaceuticals, please contact:

Mark Vignola
+1-646-747-1000
investors@interceptpharma.com

Media inquiries: media@interceptpharma.com

Ads

You May Also Like

MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage ...

Humanigen Announces Positive Topline Study Results

Study Demonstrates that GM-CSF Blockade in Combination with Chimeric Antigen Receptor T Cell Therapy ...

Precision Therapeutics Reports Third Quarter 2018 Financial Results

MINNEAPOLIS, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or ...